Volume 13, Number 1—January 2007
Gastroenteritis Caused by Norovirus GGII.4, the Netherlands, 1994–2005
Highlight and copy the desired format.
|EID||Siebenga JJ, Vennema H, Duizer E, Koopmans M. Gastroenteritis Caused by Norovirus GGII.4, the Netherlands, 1994–2005. Emerg Infect Dis. 2007;13(1):144. https://dx.doi.org/10.3201/eid1301.060800|
|AMA||Siebenga JJ, Vennema H, Duizer E, et al. Gastroenteritis Caused by Norovirus GGII.4, the Netherlands, 1994–2005. Emerging Infectious Diseases. 2007;13(1):144. doi:10.3201/eid1301.060800.|
|APA||Siebenga, J. J., Vennema, H., Duizer, E., & Koopmans, M. (2007). Gastroenteritis Caused by Norovirus GGII.4, the Netherlands, 1994–2005. Emerging Infectious Diseases, 13(1), 144. https://dx.doi.org/10.3201/eid1301.060800.|
From 1994 through 2005, gastroenteritis outbreaks caused by norovirus generally increased in the Netherlands, with 3 epidemic seasons associated with new GGII.4 strains. Increased percentages of GGII.4 strains during these epidemics, followed by a sharp decrease in their absolute and relative numbers, suggest development of immunity.
Noroviruses (NoVs) cause large outbreaks of gastroenteritis in settings of close human contact such as hospitals, institutions, military bases, and cruise ships, as well as sporadic cases. In recent years, human NoVs have increasingly been recognized as a common cause of gastroenteritis. Since the introduction of rapid molecular detection techniques, a high proportion of acute gastroenteritis outbreaks have been attributed to NoVs (1–3). We describe trends in occurrence of NoV in the Netherlands, with a focus on the predominant GGII.4 strains.
Surveillance of viral gastroenteritis outbreaks was initiated just over a decade ago at the National Institute for Public Health and the Environment in the Netherlands (RIVM). Outbreaks were typically reported by the municipal health service or the food inspection services to the RIVM, and samples were collected in close collaboration with these agencies. To determine the role of NoV and possible differences between different NoV strains in gastroenteritis outbreaks, a minimal set of epidemiologic data (setting, date of onset, number of persons affected, most probable mode of transmission, and number of hospitalizations) was collected for reported outbreaks. These data were supplemented with results of molecular biologic detection and typing techniques to enable more in-depth analysis of surveillance data.
Preliminary typing of strains was performed by sequencing region A (280 nt in the polymerase gene) of the virus. A systematic selection of strains was also typed by sequencing region C (277 nt in the capsid gene) (1,2). Because NoV activity is much higher in winter months, seasons were analyzed from July through June, rather than per calendar year.
From December 18, 1993 to December 26, 2005, a total of 1,032 gastroenteritis outbreaks were reported to the RIVM. Samples from 942 outbreaks were received and analyzed. Of these, 695 (74%) outbreaks met our inclusion criteria for a NoV outbreak (≥25% of samples positive by reverse transcription–PCR). Overall, we observed an increasing trend in the number of reported outbreaks per year (Figure, panel A). In the 1995–96, 2001–02, 2002–03, and 2004–05 seasons, more NoV outbreaks were reported (66, 90, 154, and 161, respectively). GGII virus strains were predominant in all years and caused 577 (91%) of 631 outbreaks with known genotypes, compared with 36 (6%) of 631 outbreaks caused by GGI or GGIV viruses and 18 (3%) of 631 outbreaks caused by mixed infections with viruses of different genotypes (Table).
GGII.4 strains have been detected since 1995, with the highest proportions observed in years with high numbers of outbreaks. In the epidemic seasons of 1995–96, 2002–03, and 2004–05 the percentages of outbreaks caused by GGII.4 were 82%, 83%, and 89%, respectively, compared with an overall average of 68% (Figure). In seasons after these epidemics, the percentage caused by GGII.4 decreased to 39% in 1996–97, 55% in 2003–04, and 32% in the first half of 2005–06. Multiple NoV genotypes co-circulated throughout the years of the study, but in postepidemic years, outbreaks caused by non-GGII.4 strains were more common (Figure, panel C). The high number of outbreaks in 2001–02 may be partially explained by emergence of a new variant of GGII.4 in the spring of 2002 (4), which caused uncharacteristically high numbers of outbreaks between April and June. The epidemic increases in the number of outbreaks and seasonality of outbreaks were mainly attributable to GGII.4. Strains with genotypes other than GGII.4 were found at similar levels throughout the year (data not shown).
A total of 548 (79%) outbreaks were reported in healthcare settings (hospitals and residential institutions) compared with 102 (15%) in nonhealthcare settings; for 45 (6%) outbreaks no data were available (Table). A total of 407 (81%) of 502 outbreaks with genotyping information in healthcare settings were caused by GGII.4 NoV strains (Table). In the nonhealthcare settings, GGII.4 was significantly less prevalent (39 [43%] of 91, p<0.0001), resulting in a relative risk at least 2.17× higher for acquiring a GGII.4 infection in a healthcare setting than in other settings.
A mode of transmission was reported for 272 (39%) outbreaks. Data confirmed that the main transmission route was person to person (60%, 163/272) (Table) (5,6). GGII.4 strains were found in 73% of person-to-person outbreaks compared with 44% of food-related outbreaks (p<0.0001). When outbreaks for which no genotype was known were counted as non-GGII.4 strains, the relative risk of finding GGII.4 in an outbreak caused by person-to-person transmission was 2.3× greater than finding it in a foodborne outbreak or relative to other genotypes. Multiple GGII NoV strains were found in 18 outbreaks (3 foodborne, 1 waterborne, 4 person-to-person, and 10 with unknown modes of transmission).
Detailed molecular epidemiologic data from long-term surveillance on NoV outbreaks are rare because NoV molecular detection techniques became available only in the mid-1990s. In our 12-year surveillance study, we observed large differences in the magnitude of the annual winter peak of NoV infection. All epidemic peaks were associated with predominance of GGII.4 strains. Although this finding has been observed in studies covering a shorter period (3,5–7), our data suggest an increase in infections with GGII.4 in recent years, particularly in healthcare settings. However, the number of outbreaks reported in healthcare settings is likely overrepresented in our study because of mandatory reporting of illness in such settings. An actual increase in the number of outbreaks cannot be proven based on passive surveillance data alone, but an increase is strongly suggested by increased prevalence of GGII.4 in recent years and supported by reported shifts in the predominant GGII.4 variant associated with large numbers of outbreaks (8).
The overall dominance of GGII.4 suggests that this genotype is more transmissible than other genotypes in healthcare settings, where close contact of many persons favors person-to-person transmission. Transmission may also be affected by poorer hygiene or greater susceptibility to infection. Increased transmissibility could result from increased levels of shedding of GGII.4 or altered stability of virus particles outside the host compared with other genotypes. Alternatively, changes in circulating viruses may lead to differences in host cell binding or immune recognition, thereby changing the dynamics of infection or size of the population at risk.
Our group and other researchers have reported the emergence of distinct GGII.4 lineages in 1995–96, 2002, and 2004 (2,4,9,10). This suggests that the changing phenotype of GGII.4 strains results in increased numbers of outbreaks (10). A detailed characterization of GGII.4 strains is ongoing to determine the molecular mechanisms involved in observed epidemiologic patterns. The marked decrease in the percentage of GGII.4 strains during seasons after epidemic seasons caused by variant strains suggests that populations may acquire immunity against these predominant strains.
The value of this surveillance dataset will increase with its continuation, as well as with its expansion as part of a European surveillance network (http://www.eufoodborneviruses.co.uk/). Future research will be directed at understanding the molecular basis for observed changes in the epidemiology of NoV and control of its spread.
Ms Siebenga is a PhD student at Erasmus University, Rotterdam, the Netherlands, and works at the National Institute for Public Health, Bilthoven, the Netherlands. Her research interests include the molecular epidemiology and evolution of noroviruses.
We thank E. de Bruin and B. van de Veer for technical assistance, L. Verhoef for assistance with statistical analysis, and A. Kroneman for assistance with databases.
This study was supported by the European Commission DG Research Quality of Life Program, Sixth Framework (SP22-CT-2004-502571).
- Vinje J, Koopmans MP. Molecular detection and epidemiology of small round-structured viruses in outbreaks of gastroenteritis in The Netherlands. J Infect Dis. 1996;174:610–5.
- Vinje J, Altena SA, Koopmans MP. The incidence and genetic variability of small round-structured viruses in outbreaks of gastroenteritis in The Netherlands. J Infect Dis. 1997;176:1374–8.
- Fankhauser RL, Noel JS, Monroe SS, Ando T, Glass RI. Molecular epidemiology of “Norwalk-like viruses” in outbreaks of gastroenteritis in the United States. J Infect Dis. 1998;178:1571–8.
- Lopman B, Vennema H, Kohli E, Pothier P, Sanchez A, Negredo A, Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant. Lancet. 2004;363:682–8.
- Blanton LH, Adams SM, Beard RS, Wei G, Bulens SN, Widdowson MA, Molecular and epidemiologic trends of caliciviruses associated with outbreaks of acute gastroenteritis in the United States, 2000–2004. J Infect Dis. 2006;193:413–21.
- Bon F, Ambert-Balay K, Giraudon H, Kaplon J, Le Guyader S, Pommepuy M, Molecular epidemiology of caliciviruses detected in sporadic and outbreak cases of gastroenteritis in France from December 1998 to February 2004. J Clin Microbiol. 2005;43:4659–64.
- Gallimore CI, Green J, Lewis D, Richards AF, Lopman BA, Hale AD, Diversity of noroviruses cocirculating in the north of England from 1998 to 2001. J Clin Microbiol. 2004;42:1396–401.
- Kroneman A, Vennema H, van Duijnhoven Y, Duizer E, Koopmans M. High number of norovirus outbreaks associated with a GGII.4 variant in the Netherlands and elsewhere: does this herald a worldwide increase? Eurosurveillance Weekly. 2004;8:041223.
- Noel JS, Fankhauser RL, Ando T, Monroe SS, Glass RI. Identification of a distinct common strain of “Norwalk-like viruses” having a global distribution. J Infect Dis. 1999;179:1334–44.
- Bull RA, Tu ET, McIver CJ, Rawlinson WD, White PA. Emergence of a new norovirus genotype II.4 variant associated with global outbreaks of gastroenteritis. J Clin Microbiol. 2006;44:327–33.
- Figure. A) Number of norovirus outbreaks reported per month in the Netherlands, 1994–2005. B) Total no. of outbreaks per season and fraction of GGII.4 outbreaks reported in the Netherlands. Total no....
- Table. Outbreaks of gastroenteritis caused by noroviruses per mode of transmission and setting, the Netherlands, 1994–2005
Please use the form below to submit correspondence to the authors or contact them at the following address:
J. Joukje Siebenga, National Institute for Public Health and the Environment, PO Box 1, 3720 BA Bilthoven, the Netherlands;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: July 01, 2010
- Page last updated: July 01, 2010
- Page last reviewed: July 01, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)